<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989258</url>
  </required_header>
  <id_info>
    <org_study_id>estPerMed 1, Breast</org_study_id>
    <nct_id>NCT03989258</nct_id>
  </id_info>
  <brief_title>Personalised Risk-based Breast Cancer Prevention and Screening</brief_title>
  <official_title>Implementation of a Model for Personalised Risk-Based Breast Cancer Prevention and Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tartu University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Tartu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Estonia Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tartu University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cohort study, applied research and T3 translational genomics to estimate the impact
      of genetic risk for breast cancer detection in the screening program. The study group base
      consists of 28 389 female participants, currently in the age-group 22-79, in the Biobank of
      Estonian Genome Centre. The study is aimed to demonstrate the usability of personalised
      approach for adjusting and stratifying screening recommendations, based on predicted genetic
      risk estimates for breast cancer in the situation, where the genome data could be available
      from all women who have given informed consent for that. The project includes both the
      detection of moderate and high hereditary breast cancer risk carriers as well as high risk
      polygenic risk-score (consisting several single nucleotide polymorphisms) carriers among
      healthy individuals for application of personalised prevention and screening strategies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of women in the population with genetically higher risk for breast cancer</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of screen-detected breast cancers in different risk groups</measure>
    <time_frame>3-years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">28389</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High monogenic breast cancer risk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High polygenic breast cancer risk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort StMG</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard mammography screening in age 50-69</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Mammography outside official screening</intervention_name>
    <description>Radiologic study</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cohort 1:

          -  Available NGS (WGS or WES) data for detection of breast cancer moderate to high
             genetic risk variants in BRCA1, BRCA2, TP53, STK11, PTEN, CDH1, ATM, PALB2, CHEK2,
             NBN, NF1 genes;

          -  Available genetic (WGS, genotyping) data for PRS calculation, participants in age
             40-74 will be further selected;

        Cohort 2:

          -  Available genotyping data;

          -  No available NGS data for BRCA1, BRCA2, TP53, STK11, PTEN, CDH1, ATM, PALB2, CHEK2,
             NBN, NF1 genes;

          -  Participants in the age group 40-74 with available genetic data for PRS calculation;

        Cohort StMG:

        â€¢ Female participants in Estonian Biobank in the age group 50-69 participating at least
        once in the current Estonian population-based screening program during 2016-2020.

        Exclusion Criteria:

        Cohort 1: breast cancer in the medical history; Cohort 2: breast cancer in the medical
        history. Cohort StMG: none.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peeter Padrik, MD, PhD</last_name>
      <phone>+3727319800</phone>
      <email>peeter.padrik@kliinikum.ee</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The North Estonia Medical Centre</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vahur Valvere, MD,PhD</last_name>
      <phone>+3726172304</phone>
      <email>vahur.valvere@regionaalhaigla.ee</email>
    </contact>
  </location>
  <location_countries>
    <country>Estonia</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 14, 2019</study_first_submitted>
  <study_first_submitted_qc>June 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>June 19, 2019</last_update_submitted>
  <last_update_submitted_qc>June 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tartu University Hospital</investigator_affiliation>
    <investigator_full_name>Peeter Padrik</investigator_full_name>
    <investigator_title>Director of the Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Screening</keyword>
  <keyword>Genetic risk</keyword>
  <keyword>Polygenic risk score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

